These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 307546)

  • 1. Effects of L-5-hydroxytryptophan in autistic children.
    Sverd J; Kupietz SS; Winsberg BG; Hurwic MJ; Becker L
    J Autism Child Schizophr; 1978 Jun; 8(2):171-80. PubMed ID: 307546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term therapy of myoclonus and other neurologic disorders with L-5-hydroxytryptophan and carbidopa.
    Van Woert MH; Rosenbaum D; Howieson J; Bowers MB
    N Engl J Med; 1977 Jan; 296(2):70-5. PubMed ID: 401457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L-5-hydroxytryptophan does not stimulate LH secretion directly from the pituitary in patients with gonadotrophin releasing hormone deficiency.
    Lado-Abeal J; Graña M; Rey C; Cabezas-Cerrato J
    Clin Endocrinol (Oxf); 1998 Aug; 49(2):203-7. PubMed ID: 9828908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and myoclonus.
    Van Woert MH; Jutkowitz R; Rosenbaum D; Bowers MB
    Monogr Neural Sci; 1976; 3():71-80. PubMed ID: 790170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats.
    Itskovitz HD; Werber JL; Sheridan AM; Brewer TF; Stier CT
    J Hypertens; 1989 Apr; 7(4):311-5. PubMed ID: 2786023
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome.
    Anders TF; Cann HM; Ciaranello RD; Barchas JD; Berger PA
    Neuropadiatrie; 1978 May; 9(2):157-66. PubMed ID: 308621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa.
    Smarius LJ; Jacobs GE; Hoeberechts-Lefrandt DH; de Kam ML; van der Post JP; de Rijk R; van Pelt J; Schoemaker RC; Zitman FG; van Gerven JM; Gijsman HJ
    J Psychopharmacol; 2008 Jun; 22(4):426-33. PubMed ID: 18308795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report.
    Anderson LT; Herrmann L; Dancis J
    Neuropadiatrie; 1976 Nov; 7(4):439-42. PubMed ID: 1087383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent.
    Growdon JH; Young RR; Shahani BT
    Neurology; 1976 Dec; 26(12):1135-40. PubMed ID: 1086988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and metabolic observations on the treatment of myoclonus with L-5-HTP and carbidopa.
    Thal L; Sharpless N; Wolfson L; Engel J; Katzman R
    Trans Am Neurol Assoc; 1976; 101():48-52. PubMed ID: 1088459
    [No Abstract]   [Full Text] [Related]  

  • 11. A novel neurodevelopmental syndrome responsive to 5-hydroxytryptophan and carbidopa.
    Ramaekers VT; Senderek J; Häusler M; Häring M; Abeling N; Zerres K; Bergmann C; Heimann G; Blau N
    Mol Genet Metab; 2001 Jun; 73(2):179-87. PubMed ID: 11386854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations.
    Thal LJ; Sharpless NS; Wolfson L; Katzman R
    Ann Neurol; 1980 Jun; 7(6):570-6. PubMed ID: 6969054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers.
    Gijsman HJ; van Gerven JM; de Kam ML; Schoemaker RC; Pieters MS; Weemaes M; de Rijk R; van der Post J; Cohen AF
    J Clin Psychopharmacol; 2002 Apr; 22(2):183-9. PubMed ID: 11910264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic disturbances in autistic disorder: L-5-hydroxytryptophan administration to autistic youngsters increases the blood concentrations of serotonin in patients but not in controls.
    Croonenberghs J; Verkerk R; Scharpe S; Deboutte D; Maes M
    Life Sci; 2005 Mar; 76(19):2171-83. PubMed ID: 15733932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. L-5-hydroxytryptophan in the treatment of anxiety disorders.
    Kahn RS; Westenberg HG
    J Affect Disord; 1985; 8(2):197-200. PubMed ID: 3157732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that the accumulation of 5-hydroxytryptamine in the liver but not in the brain may cause the hypoglycaemia induced by 5-hydroxytryptophan.
    Endo Y
    Br J Pharmacol; 1985 Jul; 85(3):591-8. PubMed ID: 3875380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
    Takahashi S; Takahashi R; Masumura I; Miike A
    Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects.
    Byerley WF; Judd LL; Reimherr FW; Grosser BI
    J Clin Psychopharmacol; 1987 Jun; 7(3):127-37. PubMed ID: 3298325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of obesity with "combination" pharmacotherapy.
    Rothman RB
    Am J Ther; 2010; 17(6):596-603. PubMed ID: 19352140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.